Otsuka Pharmaceutical: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
| romanized_name = Ōtsuka Seiyaku Kabushiki-gaisha | | romanized_name = Ōtsuka Seiyaku Kabushiki-gaisha | ||
| former_name = | | former_name = | ||
| type = [[Public company|Public]] [[Kabushiki gaisha|KK]] | | type = [[:en:Public company|Public]] [[:en:Kabushiki gaisha|KK]] | ||
| traded_as = {{TYO|4578}}<br>[[TOPIX|TOPIX 100 Component]] | | traded_as = {{TYO|4578}}<br>[[TOPIX|TOPIX 100 Component]] | ||
| ISIN = | | ISIN = | ||
| industry = [[Pharmaceutical industry|Pharmaceutical]] | | industry = [[Pharmaceutical industry/ja|Pharmaceutical]] | ||
| genre = | | genre = | ||
| fate = | | fate = | ||
| Line 22: | Line 22: | ||
| founder = Busaburo Otsuka | | founder = Busaburo Otsuka | ||
| defunct = | | defunct = | ||
| location_city = [[ | | location_city = [[:ja:東京都|東京都]][[:ja:千代田区|千代田区]] | ||
| location_country = [[ | | location_country = [[:ja:日本|日本]] | ||
| location = | | location = | ||
| coordinate = | | coordinate = | ||
| locations = 69 | | locations = 69 | ||
| area_served = Worldwide | | area_served = Worldwide | ||
| key_people = Tatsuo Higuchi <small>([[President (corporate title)|President]])</small> | | key_people = Tatsuo Higuchi <small>([[:en:President (corporate title)|President]])</small> | ||
| products = | | products = | ||
| brands = | | brands = | ||
| Line 45: | Line 45: | ||
| equity = | | equity = | ||
| equity_year = | | equity_year = | ||
| owner = [[Nomura Trust and Banking]] [[investment trusts]] (11.43%)<br>''and investment trusts managed by other banks'' | | owner = [[Wikipedia:Nomura Trust and Banking|Nomura Trust and Banking]] [[Wikipedia:investment trusts|investment trusts]] (11.43%)<br>''and investment trusts managed by other banks'' | ||
| num_employees = 5,634 | | num_employees = 5,634 | ||
| num_employees_year = 2017 | | num_employees_year = 2017 | ||
| Line 54: | Line 54: | ||
| footnotes = | | footnotes = | ||
}} | }} | ||
{{nihongo|'''Otsuka Pharmaceutical Co., Ltd.'''|大塚製薬株式会社|Ōtsuka Seiyaku Kabushiki-gaisha}} ({{Tyo|4578}}), abbreviated '''OPC''', is a [[pharmaceutical company]] headquartered in [[Tokyo]], [[Osaka]] and [[Naruto, Tokushima|Naruto]], [[Japan]]. The company was established August 10, 1964. | {{nihongo|'''Otsuka Pharmaceutical Co., Ltd.'''|大塚製薬株式会社|Ōtsuka Seiyaku Kabushiki-gaisha}} ({{Tyo|4578}}), abbreviated '''OPC''', is a [[pharmaceutical company]] headquartered in [[Tokyo]], [[Osaka]] and [[:en:Naruto, Tokushima|Naruto]], [[Japan]]. The company was established August 10, 1964. | ||
==History== | ==History== | ||
OPC's parent company Otsuka Holdings Co. Ltd. joined the [[Tokyo Stock Exchange]] through an [[initial public offering]] (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader [[Takeda Pharmaceutical Company]]. | OPC's parent company Otsuka Holdings Co. Ltd. joined the [[Tokyo Stock Exchange]] through an [[initial public offering]] (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader [[Takeda Pharmaceutical Company]]. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time. | ||
===Otsuka Pharmaceutical Co. Ltd Holdings=== | ===Otsuka Pharmaceutical Co. Ltd Holdings=== | ||
In 1955, the company started a [[football (soccer)|football]] club called "Otsuka Pharmaceutical SC." In 2005 the name changed to [[Tokushima Vortis]]. The club is based in Naruto. | In 1955, the company started a [[football (soccer)|football]] club called "Otsuka Pharmaceutical SC." In 2005 the name changed to [[Tokushima Vortis]]. The club is based in Naruto. | ||
In 1986, Otsuka Holdings Co. Ltd. acquired [[Ridge Vineyards]]. | In 1986, Otsuka Holdings Co. Ltd. acquired [[Ridge Vineyards]]. | ||
In 1990, Otsuka Holdings Co. Ltd. acquired [[Crystal Geyser Water Company]]. | In 1990, Otsuka Holdings Co. Ltd. acquired [[Crystal Geyser Water Company]]. | ||
In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of [[CG Roxane]]. | In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of [[CG Roxane]]. | ||
In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". | In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology". This decision necessitated a revision in the terms of an agreement with [[UCB (company)|UCB]] to end collaboration on immunology products while continuing collaboration in the CNS area. | ||
In September 2013, Otsuka Holdings it acquired [[Astex|Astex Pharmaceuticals]] for close to $900 million.<ref>{{cite news| url= https://www.reuters.com/article/us-astex-offer-otsuka-idUSBRE98407Q20130905| title= Japan's Otsuka to buy cancer drug maker Astex Pharma| author= Tim Kelly| publisher=Reuters | date=5 September 2013}}</ref> | In September 2013, Otsuka Holdings it acquired [[Astex|Astex Pharmaceuticals]] for close to $900 million.<ref>{{cite news| url= https://www.reuters.com/article/us-astex-offer-otsuka-idUSBRE98407Q20130905| title= Japan's Otsuka to buy cancer drug maker Astex Pharma| author= Tim Kelly| publisher=Reuters | date=5 September 2013}}</ref> | ||
In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion. | In December 2014, Otsuka Holdings struck a deal to buy Avanir Pharmaceuticals for $3.54 billion. | ||
In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary. | In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready [[ADHD]] drug [[centanafadine]] (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary. | ||
In July 2017, the business acquired [[Daiya]]. | In July 2017, the business acquired [[Daiya]]. | ||
In July 2018, Otsuka agreed to acquire Visterra for $430 million cash | In July 2018, Otsuka agreed to acquire Visterra for $430 million cash and renal-focused ReCor Medical, Inc. | ||
In August 2023, the company announced its intention to acquire Mindset Pharma Inc for up to CAD$80 million. | In August 2023, the company announced its intention to acquire Mindset Pharma Inc for up to CAD$80 million. | ||
| Line 106: | Line 106: | ||
* [[Pocari Sweat]] | * [[Pocari Sweat]] | ||
* [[Oronamin C]] | * [[Oronamin C]] | ||
* [[Aripiprazole|Aripiprazole / Abilify]] | * [[Aripiprazole|Aripiprazole / Abilify]] | ||
==External links== | ==External links== | ||